Insight into the behavior of hairy cell leukemia by immunogenetic analysis

References

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609–630.
   PubMed Web of Science ®Google Scholar
• Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869–1870.
   PubMed Web of Science ®Google Scholar
• Forconi F, Raspadori D, Lenoci M, Lauria F. Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica 2005;90:266–268.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edLyon: IARC; 2008. p 441.
   Google Scholar
• Rajewsky K, von Boehmer H. Lymphocyte development:overview. Curr Opin Immunol 2008;20:127–130.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 2001;83:81–116.
   PubMed Web of Science ®Google Scholar
• Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol 2006;133:504–512.
   PubMed Web of Science ®Google Scholar
• Thorselius M, Walsh SH, Thunberg U, Hagberg H, Sundstrom C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res 2005;29:153–158.
   PubMed Web of Science ®Google Scholar
• Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica 2008;93: 697–705.
   PubMed Web of Science ®Google Scholar
• Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696–4702.
   PubMed Web of Science ®Google Scholar
• Maloum K, Magnac C, Azgui Z, et al. VH gene expression in hairy cell leukaemia. Br J Haematol 1998;101:171–178.
   PubMed Web of Science ®Google Scholar
• Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood 2001;98:1174–1181.
   PubMed Web of Science ®Google Scholar
• Vanhentenrijk V, Tierens A, Wlodarska I, Verhoef G, Wolf-Peeters CD. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia 2004;18:1729–1732.
   PubMed Web of Science ®Google Scholar
• Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood 2004;104:3312–3317.
   PubMed Web of Science ®Google Scholar
• Kayano H, Dyer MJ, Zani VJ, et al. Aberrant rearrangements within the immunoglobulin heavy chain locus in hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl. 1):41–47.
   PubMed Web of Science ®Google Scholar
• Haak HL, de Man JC, Hijmans W, Speck B. Further evidence for the lymphocytic nature of leukaemic reticuloendotheliosis (hairy-cell leukaemia). Br J Haematol 1974;27:31–38.
   PubMed Web of Science ®Google Scholar
• Burns GF, Cawley JC, Worman CP, et al. Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood 1978;52:1132–1147.
   PubMed Web of Science ®Google Scholar
• Golomb HM, Davis S, Wilson C, Vardiman J. Surface immunoglobulins on hairy cells of 55 patients with hairy cell leukemia. Am J Hematol 1982;12:397–401.
   PubMed Web of Science ®Google Scholar
• Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993;82:1277–1287.
   PubMed Web of Science ®Google Scholar
• Sozzi E, Amato T, Sahota SS, et al. Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia. Hematol Oncol 2011;29:31–37.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006;6:437–448.
   PubMed Web of Science ®Google Scholar
• Berek C. The development of B cells and the B-cell repertoire in the microenvironment of the germinal center. Immunol Rev 1992;126:5–19.
   PubMed Web of Science ®Google Scholar
• MacLennan IC, Toellner KM, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev 2003;194: 8–18.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004;5:1523–1533.
   PubMed Web of Science ®Google Scholar
• Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl. 1):121–125.
   PubMed Web of Science ®Google Scholar
• Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891–896.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733–740.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 2009;15:2652–2664.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27: 2983–2990.
   PubMed Web of Science ®Google Scholar
• Lauria F, Forconi F. Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma 2009;50(Suppl. 1):18–22.
   PubMed Web of Science ®Google Scholar
• Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep 2006;8:337–342.
   PubMedGoogle Scholar
• Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83: 3672–3681.
   PubMed Web of Science ®Google Scholar
• Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994;120:784–791.
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810–813.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004;89:309–313.
   PubMed Web of Science ®Google Scholar
• Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442–2448.
   PubMed Web of Science ®Google Scholar
• Forconi F, Poretti G, Kwee I, et al. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol 2008;141:622–630.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389–4395.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Sherrington PD, Cawley JC. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999;106:1049–1051.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–967.
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322–3329.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall Survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Kienle D, Krober A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003;102:3003–3009.
   PubMed Web of Science ®Google Scholar
• Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101:4975–4981.
   PubMed Web of Science ®Google Scholar
• Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003;21:3928–3932.
   PubMed Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–1416.
   PubMed Web of Science ®Google Scholar
• Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687–4695.
   PubMed Web of Science ®Google Scholar